Autobahn Therapeutics trial shows elunetirom improves bipolar depression symptoms
Autobahn Therapeutics announced full results from its Phase 2 AMPLIFY-BD trial, showing elunetirom improved depressive symptoms and functioning in patients with bipolar depression. The drug is generally well-tolerated with no severe treatment-related adverse events.